Oncology Pharma extends licensing agreement with NanoSmart Pharmaceuticals, Inc. for veterinary oncology

▴ Oncology Pharma extends licensing agreement with NanoSmart Pharmaceuticals, Inc. for veterinary oncology
This collaboration will improve the field of the animal healthcare industry

Oncology Pharma, Inc. is pleased to announce that it has extended a world-wide Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for use in the growing Veterinary Oncology market.

Nanosmart possesses proprietary technology and intellectual property rights for the development of liposomal and/or emulsion-based drug formulations that incorporate anti-nuclear antibodies (ANA).

The global veterinary oncology market size was estimated at USD 199.9 million in 2019 and is anticipated to witness a Compound Annual Growth Rate (CAGR) of 10.7% over the next decade. A major driver of the market growth is the increasing prevalence of cancer in the pet population paired with the rising adoption of veterinary cancer therapy. Additionally, developed economies are spending more on animal healthcare due to pet owners’ rising willingness to spend on pet healthcare and government initiatives for veterinary cancer treatment.

ANA may be utilized as a targeting agent in pharmaceutical compounds to deliver active pharmaceutical ingredients to tumour sites, potentially resulting in safer and more effective cancer therapies. ANA-conjugated formulations like those licensed from NanoSmart present an opportunity to deliver better healthcare options for a growing and receptive market.

Oncology Pharma is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.

Tags : #OncologyPharma #LatestNewsonOncologyPharma23rdFeb #NanoSmartPharmaceuticals #LatestNewsonNanoSmartPharmaceuticals23rdFeb #LatestPharmaCollaboration23rdFeb #LatestPharmaNews23rdFeb #AnimalHealhcareIndustry #VeterinaryCancerTherapy

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026